Skip to search formSkip to main contentSkip to account menu

Salicylamides

Known as: Salicylamides [Chemical/Ingredient] 
Amides of salicylic acid.
National Institutes of Health

Related topics

Related topics

30 relations

Narrower (24)

3-iodo-4-azido-N-hexadecylsalicylamideFLA 797FLB 457FLB 463
In Bloodagonistsantagonists & inhibitorsaspects of radiation effects

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
2012
2012
Crystal Structure of the 5-Chloro Salicylamides: Three Different Types of the H-bonding Influenced Linear Chain Formation in the Solid State
Three N-substituted 5-chlorosalicylamides (4-chlorophenyl, 2a; benzyl, 2b; phenethyl 2c) differing in the length of the 'linker… 
2001
2001
Synthesis and evaluation of the analgesic and antiinflammatory activities of O-substituted salicylamides.
The present investigation deals with the synthesis of some new salicylamidoacetyl sulfonamides 3a,b, salicylamido ethylacetate 4… 
1994
1994
Salicylamides Containing Amino Acid or Pyran Moieties with Molluscicidal Activity
Salicylamide amino acid conjugates were prepared utilizing 5‐formyl‐, 5‐dicyanoethenyl‐, and 5‐nitroethenylsalicylic acid. 5… 
1991
1991
Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other…
A number of substituted N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides and -salicylamides have been prepared and investigated as… 
1990
1990
Syntheses of [123I]-, [125I]- and unlabelled (S)-3-iodo-5,6-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]salicylamide (NCQ 298), selective ligands for the study of dopamine D-2 receptors.
The salicylamide NCQ 298, (S)-3-iodo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5,6-dimethoxysalicylami de (4), binds with a high… 
1990
1990
Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds…
(S)-5-Bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide (6) and some related compounds, i.e. the R isomer 7, the 3… 
1987
1987
Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine‐D2 antagonist *
The structure of the potent dopamine‐D2 antagonist, raclopride, (S)‐3,5‐dichloro‐N‐[(1‐ethyl‐2‐pyrrolidinyl)methyl]‐6… 
Highly Cited
1982
Highly Cited
1982
Arylethanolamines derived from salicylamide with alpha- and beta-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers, and related salicylamides.
A series of phenethanolamines (3) based on salicylamide has been prepared and shown to possess beta-adrenergic blocking… 
1969
1969
Ring opening of cyclic salicylamides.
The ring opening of four cyclic salicylamides to their phenolic analogs is described. Compounds in which a basic group is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)